INZY Stock Discussion
Inozyme Pharma, Inc. Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as in the early stages of development for calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Disease Pharmacy Molecular Biology Specialty Drugs Genetic Diseases Rare Genetic Disease Rare Genetic Diseases Recombinant Dna
Recent Comments
- SuccessfulGrasshopper897 on Stochastic Reached Oversold
- Cos3 on Adding float as advanced filter criteria?
- FriendlyOyster657 on BOOT
- TraderMike on Filtering by News?
- Dr_Duru on Filtering by News?
From the Blog
Featured Articles